Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

NeuExcell Raises $10 Million For Gene Therapies Aimed at Neurodegenerative Repair

publication date: Sep 2, 2021

NeuExcell Therapeutics, a Pennsylvania-Shanghai gene therapy company focused on neurodegenerative diseases, completed a $10+ million Series Pre-A financing from China investors. Based on the scientific work of the company's co-founder and Chief Scientific Advisor, Prof. Gong Chen, NeuExcell has developed a neuron repair technology via in vivo astrocyte-to-neuron conversion. The technology delivers neural transcription factor(s) using an adeno-associated virus (AAV). The round was led by Co-Win Ventures and included YuanBio, Oriza Seed, Tsingyuan and InnoAngel. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China